Paris, Dec 9 (EFE) .- The French pharmaceutical giant Sanofi announced Monday the purchase of the American company Synthorx, specializing in drugs against cancer and autoimmune diseases, for about 2.5 billion dollars.
The operation, which has received the unanimous approval of the boards of directors of both companies, will be carried out in a S anofi bid for all of Syhnthorx's outstanding shares at a price of $ 68 each to be paid in cash.
That means a premium of 172% compared to the price at the close of the stock market last Friday and means giving the company a value of about 2,350 million dollars, both groups said in a joint statement.RELATED
The bid will be launched this December and should be completed in the first quarter of 2020. Sanofi will finance it with its own treasury.
For the general director of the French group, Paul Hudson, this acquisition fits "perfectly" with his strategy of "energizing innovation and building a portfolio composed of high quality medicines".
Also with the aim of providing its oncological franchise with 'medicines that have the potential to change the practice of medicine, as well as innovative therapeutic associations'. EFE